Alexion Pharmaceuticals (AXLN) Announces Interim Results from Phase I/II Trial of Samalizumab
Go back to Alexion Pharmaceuticals (AXLN) Announces Interim Results from Phase I/II Trial of SamalizumabAlexion Pharmaceuticals (NASDAQ: ALXN) | Delayed: 182.01 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $182.01 | 52 Week High | $193.45 | |||
Open | $33.31 | 52 Week Low | $110.56 | |||
Day High | $182.01 | P/E | 143.31 | |||
Day Low | $182.01 | EPS | $1.27 | |||
Volume | 71 |
(AMEX: AXLN) | Delayed: 0.00 --0 (-0%) | |||||
---|---|---|---|---|---|---|
Previous Close | $0.00 | 52 Week High | $ | |||
Open | $0.00 | 52 Week Low | $ | |||
Day High | $0.00 | P/E | N/A | |||
Day Low | $0.00 | EPS | $ | |||
Volume | 0 |